A clinical trial of testosterone treatment in older men, reported June 30 online in the New England Journal of Medicine, has found a higher rate of adverse cardiovascular events, such as heart attacks and elevated blood pressure, in a group of older men receiving testosterone gel compared to those receiving placebo. Due to these...
In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.
In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment...
On National HIV Testing Day, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, urges everyone between the ages of 13 and 64 years to be tested for HIV at least once in their lifetime in keeping with the recommendation of the Centers for Disease Control and...
An intervention in middle schools lowered the obesity rate in students at highest risk for type 2 diabetes, those who started out overweight or obese in sixth grade, an NIH-funded study has found.
The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, announced the availability of supplemental funding for eligible NIBIB-supported research grants to facilitate collaborative work among researchers in the United States and India.
BATON ROUGE, La.–NEWS–Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health and hospice companies, today announced that it has received notice of a formal investigation from the Securities and Exchange Commission (SEC) pertaining to the company, and received a subpoena for documents relating to the matters under review by the Senate Finance Committee....
BENSALEM, Pa.–NEWS–Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Abraxis BioScience, Inc. (“Abraxis” or the “Company”) (NASDAQ:ABII) related to the Company’s agreement to be acquired by Celgene Corporation (“Celgene”). The proposed cash-and-stock transaction is valued at approximately $2.9 billion. Under the terms of...
BOSTON–NEWS–A Massachusetts man today filed a class action lawsuit in U.S. District Court in Boston claiming injuries as a result of using Zicam Cold Remedy Gel.
PERTH, Western Australia–NEWS–Amcom Fusion 2.4 enables key clinical and safety systems to integrate with the latest devices carried by mobile staff. Expanded support for KIRK and other Polycom phone systems increases flexibility.